In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
about
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsAn update on the management of urinary tract infections in the era of antimicrobial resistance.Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against Carbapenem-Non-Susceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014-2016.In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).In Vitro Activity of Ceftazidime-Avibactam Against Isolates from Patients in a Phase 3 Clinical Trial for the Treatment of Complicated Intra-Abdominal Infections.Avibactam Pharmacokinetic/Pharmacodynamic Targets.Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
P2860
Q28069563-4848CA5B-BCCB-4FD1-8567-BD6E568931A3Q30244815-2C677F86-2DEE-40D9-9E9C-67C0EFDD2875Q33816251-A5676750-F7C1-402C-8C9E-7BFDA78F8B19Q39183212-1430AEBC-A9C4-4D9A-B7CF-F9A12C5A6533Q40163436-09F3791B-7493-419D-8EC0-6DC46B01E263Q40282001-995603E2-0B22-458F-BCFB-96ECB18899A8Q40595790-20A2BC0D-D8B8-447B-A279-FFDB540987B2Q42638031-0504F1EB-6D3B-4D7C-AB3A-357206E78581Q46267269-2922E8F4-A905-4A36-9322-047E022E1CF2Q47129277-AAAD3AE0-FD35-45A3-BF73-AD77C56BAB9FQ47211519-154BACD2-45B9-4412-B4D6-1245626B11B7Q47341827-EAADD2E7-BE37-4731-A3B4-76C63DB7CE4BQ52568634-599394A7-A2C0-47BC-B6AD-8E8CE5E8BB81Q52611981-96075442-5D17-4D54-86CD-1010E2A575ADQ57211457-4455CA34-4CC7-4224-BCEB-5417F8802B61
P2860
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
In Vitro Susceptibility to Cef ...... eillance Study (2012 to 2014).
@en
type
label
In Vitro Susceptibility to Cef ...... eillance Study (2012 to 2014).
@en
prefLabel
In Vitro Susceptibility to Cef ...... eillance Study (2012 to 2014).
@en
P2093
P2860
P356
P1476
In Vitro Susceptibility to Cef ...... eillance Study (2012 to 2014).
@en
P2093
Boudewijn L M de Jonge
Daniel F Sahm
Douglas J Biedenbach
James A Karlowsky
Krystyna M Kazmierczak
Wright W Nichols
P2860
P304
P356
10.1128/AAC.03042-15
P407
P577
2016-02-29T00:00:00Z